Transforming Global Literature Monitoring with Medically Tuned AI

Modernizing Evidence Monitoring for a Global Leader

In the rapidly evolving landscape of clinical research, a Top 10 pharmaceutical company faced a critical challenge: their manual processes could no longer keep pace with the exponential growth of published medical data. Partnering with Sorcero, this organization transitioned from a fragmented, episodic approach to a continuous, AI-augmented monitoring workflow. Originally validated within the oncology therapeutic area, the solution has since scaled across the enterprise, including Vaccines & Immunology (V&I), Cardiovascular, Renal, and Metabolism (CVRM), and Respiratory & Immunology (R&I).

The Operational Burden: Challenges of Manual Publication Monitoring

The organization’s medical affairs and publications teams were previously tasked with an unsustainable workload that hindered strategic agility. Within the oncology division alone, the sheer pace of research required the review of over 4,000 literature articles every week just to maintain current knowledge of global breakthroughs. Executing this volume of work through traditional manual methods was estimated to require the equivalent of 50 full-time scientists, creating an operational bottleneck for the existing team.

Furthermore, these manual efforts were often time-bound and episodic, making it difficult to identify long-term clinical trends or competitive shifts in real-time. This reliance on labor-intensive data collection risked the omission of critical insights necessary for evidence generation and publication planning.

The Solution: Intelligent Literature Monitoring (ILM) Powered by Medically Tuned AI

The organization deployed Sorcero’s Intelligent Literature Monitoring (ILM) solution to unify and enrich their scientific monitoring. Key features include:

Unified Global Data Access: Integration of over 250 million publications from 20+ diverse sources, including clinical trials, journals, and preprint servers.
Advanced Biomedical Ontologies: The platform utilizes medically tuned ontologies and tags, allowing the AI to understand complex clinical nuances and therapeutic contexts.
Comprehensive Functional Support: The tool is designed to support a wide array of medical functions, including Field Medical, Publications, HEOR, Medical Information, and Senior Leadership.
Enhanced Insight Delivery: The system generates literature reviews, congress summaries, clinical trial reviews, and evidence gap analyses that were previously limited by manual reporting.

Quantifiable Performance: Exceeding Regulatory-Grade Benchmarks

The transition to an AI-driven workflow provided not only speed but also the precision required for regulatory compliance. Performance results include:

Regulatory-Grade Accuracy: The platform achieved 99.83% sensitivity and 96.1% Negative Predictive Value (NPV), exceeding the 95% threshold required for regulatory-grade literature review solutions.
Superior Relevancy: In head-to-head comparisons with standard models like BioBERT, the Sorcero LI platform demonstrated an 11.5% absolute performance advantage in relevancy scoring for subjects and intended use.
Dramatic Efficiency Gains: Manual review time for M.D. and PhD-level staff was reduced from an average of 27 minutes per article (715 total hours) to a highly optimized process requiring only 80 combined hours of review and QA—an 88% total reduction in effort.

See the published research from Sorcero, Moderna, and Coherus Biosciences comparing Sorero ILM solution with alternative literature monitoring methods ->

Enterprise Expansion: Scaling Across Complex Therapeutic Landscapes

Following the success in Oncology, the organization leveraged deep institutional knowledge—including specific search strings and search frames—to scale the platform across its global portfolio. This enterprise-wide adoption has unified how the company monitors the therapeutic landscape in V&I, CVRM, and R&I, ensuring that every division benefits from the same high-fidelity data and accelerated insight generation.

Business Impact: Shifting from Data Collection to Strategic Insight

The implementation of an AI-driven monitoring solution enables the medical organization to pivot from reactive data management to proactive therapeutic leadership.

Expert Resource Optimization: By automating the initial screening and relevancy scoring of thousands of weekly articles, M.D. and PhD-level experts can shift their primary focus from rote administrative filtering to the interpretation of complex clinical implications.
Enhanced Strategic Alignment: The platform delivers 80% greater efficiency in identifying and mapping specific research trends to the organization’s core annual medical objectives, ensuring that internal resources are always focused on high-priority evidence.
Accelerated Evidence Generation: Transitioning from episodic, time-bound reviews to an instant insight engine allows medical affairs, publication, and HEOR teams to identify research gaps immediately, significantly reducing the time required to move from data ingestion to actionable medical strategy.

The AI Imperative for Medical Affairs

This partnership demonstrates that AI is no longer a peripheral tool but a core strategic necessity for global pharmaceutical leaders. By reclaiming hundreds of hours of expert time and ensuring 99.83% sensitivity, the organization has created a complete, real-time view of the healthcare landscape. Ultimately, this enables more confident decision-making and accelerates the delivery of breakthrough treatments to the patients who need them most.

Transforming Global Literature Monitoring with Regulatory-Grade Medically Tuned AI